ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CGEM / forecast
ODTX (52) PRME (31) MGTX (21) GLUE (27) ⌘ Pro Terminal →

Cullinan Therapeutics Inc. (CGEM) 12-Month Stock Forecast & Price Target Cone

$15.03 -2.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.93

Cullinan Therapeutics Inc. (CGEM) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $994.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CGEM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CGEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $15.03 (-2.72% 1D, market cap $994.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CGEM ranks #772 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CGEM compare to ODTX and PRME in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $953.0M) and PRME (Prime Medicine Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CGEM?
▼

Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $0 in revenue, -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.93 (-0.68%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (7)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$24 Bull$13 Base$10 Bear
📬 FREE CGEM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CGEM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY CGEM SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
24
Grade E$14.95-6.5% Next Q
Q2 (-2Q)
27
Grade E$13.98+4% Next Q
Q3 (-1Q)
29
Grade E$14.54+3.4% Next Q
Current
32
Grade E$15.03-9.2% Hist 90D α
Trajectory: E (24) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CGEM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CGEM currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.78) and Max Pain ($15.78) forces dealer call-delta covering toward $24.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CGEM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CGEM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CGEM Position Size: $10,000

Shares at $15.03: 665.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $10.35
$6,886
$-3,114 (-31.1%)
12M Consensus BaseTarget $13.27
$8,829
$-1,171 (-11.7%)
12M Bull Case BreakoutTarget $24.35
$16,201
+$6,201 (+62.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1474%A
Goldman SachsSector Coverage LeadUNDERPERFORM$2369%B
JP MorganUS Large-Cap ResearchSELL$1258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CGEM)

  • ✓Walkthrough of CGEM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CGEM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.02%📐 HORIZONTAL RANGE
2026-11-02O $15.56H $15.56L $15.03C $15.03VOL 460.1K
RES: $27.40SUP: $12.27SMA50: $17.78SMA200: $15.83
$24.09$20.36$16.63$12.89$9.16RES $27.40SUP $12.27$15.032026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CGEM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CGEM Butterfly Map → + Track CGEM →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CGEM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CGEM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CGEM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CGEM)

Health Care Rank #772 of 1016 ⚔️ ODTX vs CGEM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CGEM vs. ODTX, PRME, MGTX, GLUE)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cullinan Therapeutics Inc. (CGEM) ranks #772 by composite RQD confidence (32/100, grade E) and #362 by equity capitalization ($994.3M). Within this direct 5-issuer industry benchmark cohort, CGEM leads on earnings valuation at N/A trailing P/E, while CGEM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CGEM at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CGEM ACTIVE
Cullinan Therapeutics Inc.
E 32/100 — — -35.0% -2.72% $994.3M Benchmark Subject
ODTX
Odyssey Therapeutics Inc.
D+ 52/100 — — — -1.46% $953.0M /odtx-vs-cgem →
PRME
Prime Medicine Inc.
E 31/100 — — -35.0% -9.92% $950.4M /prme-vs-cgem →
MGTX
MeiraGTx Holdings plc
E 21/100 — — -35.0% -2.21% $932.1M /mgtx-vs-cgem →
GLUE
Monte Rosa Therapeutics Inc.
E 27/100 — — -35.0% -1.01% $927.4M /glue-vs-cgem →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001789972

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cullinan Therapeutics Inc. (CGEM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$219.9M, operating cash flow of -$175.8M, and free cash flow of -$175.8M (-21.0% YoY). On the balance sheet, CGEM closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$219.9M -$175.8M -$175.8M $448.4M —
FY2024 (FY) 2024-12-31 $0 -$167.6M -$145.3M -$145.3M $621.8M —
FY2023 (FY) 2023-12-31 $0 -$155.1M -$134.3M -$134.3M — —

3. CGEM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CGEM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $15.03 (-2.72% 1D, market cap $994.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CGEM ranks #772 in composite RQD confidence.

How does CGEM compare to ODTX and PRME in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $953.0M) and PRME (Prime Medicine Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CGEM?

Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $0 in revenue, -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CGEM trading relative to its 50-day, 200-day, and 52-week technical levels?

CGEM last traded at $15.03 (-2.72% on volume of 389,442 shares), positioning the stock -15.47% below its 50-day simple moving average ($17.78) and -5.05% below its 200-day simple moving average ($15.83). Across its 52-week range of $6.73 to $23.19, CGEM sits at the 50.4% percentile with a 14-day RSI of 48.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.15 to $16.91).

CGEM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CGEM's 12-month stock price target?

Cullinan Therapeutics Inc. (CGEM) carries a 12-month consensus base price target of $13.27 (-11.7% from $15.03), with a bull-case target of $24.35 and a bear-case floor of $10.35.

Is CGEM stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CGEM E (Strong Sell — SELL) with an RQD Confidence score of 32/100.

Direct Sub-Reports: CGEM RQD Cockpit CGEM 12M Forecast CGEM Earnings & Move CGEM Dividends & DRIP CGEM Insiders & 13F CGEM Whale Options CGEM Profit Sankey CGEM News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CGEM — Cullinan Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:31:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CGEM scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows:

  • Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -17.68%. For a prospective investor, the implication is that the business is currently consuming capital rather than generating it; any valuation case must rest on future cash generation that the source data does not demonstrate.
  • Whale 13F Flow: 7 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, indicating limited institutional conviction as reflected in the rating inputs.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The lowest pillar score signals weak insider-level conviction; the source data does not provide the underlying transaction detail.
  • Macro Regime Fit: 5 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. The score indicates limited favorable alignment with the current macro regime in the rating's framework.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2 of 9, and Debt/Equity is 0.5. This is the highest pillar but still sub-50%, reflecting weak accounting-quality signals.

Investment implication: the rating frames CGEM as a forensic-risk name. Upside would require a reversal in cash burn and insider/institutional conviction, none of which the source data shows as having begun. Valuation tradeoffs center on a $994.3M market capitalization against negative operating and free cash flow; the absence of earnings-based multiples means conventional valuation anchors cannot be applied from the source data alone.

Business

Cullinan Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. The source data does not identify its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M across the available periods, so the source data does not show commercial sales.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-241.6M$-219.9MN/A$-175.8M$88.3MN/A
FY 2024$0.0M$-196.9M$-167.6MN/A$-145.3M$83.0MN/A
FY 2023$0.0M$-191.1M$-155.1MN/A$-134.3MN/AN/A

Per the SEC financials, the company reported operating and net losses in every period shown, with losses widening from FY 2023 to FY 2025. Gross, operating, and net margins are each 0% per the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2 of 9. Per the SEC financials, reported cash was $88.3M at FY 2025, and the source data does not provide debt figures for any period.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts data, five items reference CGEM, each tagged YELLOW with a MARKET WIRE impact label, from sources including Yahoo! Finance Canada, Yahoo Finance UK, TradingView, Simply Wall St, and MarketBeat. Headlines reference stock price and news coverage, a shares gap-up report, an FDA filing progress analysis, and a BTIG Buy rating with a $41 price target. The summaries are generic market-coverage descriptions and do not contain specific trial, filing, or financing details. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream or downstream dependencies, sector correlations, or second-order bottlenecks. The only sector context is the classification itself: Health Care, Biotechnology: Biological Products. A prospective investor should note that FDA-related coverage appears in the news wire, but the source data does not connect that coverage to any specific supply-chain node.

Analyst View & Smart Money Ownership

Per the analyst data section, no analyst data is available. The news wire references a BTIG Buy rating with a $41 price target, but the analyst data section itself is empty and does not provide a consensus rating. Per the holders section, no holder data is available, so SEC Form 4 insider trades, 13F institutional holdings, and Congressional trades are not available in source data.

Open Questions

  • What are CGEM's products and clinical or regulatory milestones, and what is the timing of the FDA filing referenced in the news wire?
  • What is the company's debt position and runway, given that cash is reported at $88.3M against FY 2025 free cash flow of $-175.8M?
  • What drove the cash burn trend from FY 2023 to FY 2025, and what is the path to positive cash flow?
  • Is the BTIG Buy rating and $41 price target from the news wire reflected in a formal analyst consensus, and what are the underlying assumptions?
  • What are the insider, institutional, and Congressional holdings and transactions behind the RQD insider and whale-flow pillar scores?

CGEM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cullinan Therapeutics Inc. (CGEM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CGEM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CGEM Bull vs. Bear Conversation Board — What's Your Call at $15.03?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CGEM 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CGEM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $13.60 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CGEM (E • RQD 32/100) a Buy at $15.45?

Welcome to the CGEM (Cullinan Therapeutics Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $11.74 (-24.0%)
Spot @ $15.45

Pump the brakes on CGEM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CGEM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cullinan Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $18.85 (+22.0%)
Spot @ $15.45

CGEM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CGEM, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $15.45 (52-wk range $6.73 - $23.19), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%